H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Century Therapeutics (IPSC) to $5 from $9 and keeps a Buy rating on the shares after the company announced updated Phase 1 data for CNTY-101 in CD19+ B cell lymphomas.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics Reports Q3 Results & Strategic Updates
- Century Therapeutics reports Q3 EPS (37c), consensus (45c)
- Century Therapeutics expects cash to support operations into 2H26
- Century Therapeutics sees FY24 GAAP operating expenses $150M-$160M
- Century Therapeutics Appoints Morgan Conn as New CFO